Characterization of V3 loop-Pseudomonas exotoxin chimeras -: Candidate vaccines for human immunodeficiency virus-1

被引:14
|
作者
Fitzgerald, DJ
Fryling, CM
McKee, ML
Vennari, JC
Wrin, T
Cromwell, MEM
Daugherty, AL
Mrsny, RJ
机构
[1] NCI, NIH, Biotherapy Sect, Mol Biol Lab,Div Basic Sci, Bethesda, MD 20892 USA
[2] Genentech Inc, Pharmaceut Res & Dev, Cell Banking, S San Francisco, CA 94080 USA
[3] Genentech Inc, Pharmaceut Res & Dev, Drug Delivery Biol, S San Francisco, CA 94080 USA
关键词
D O I
10.1074/jbc.273.16.9951
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To develop a candidate vaccine for human immunodeficiency virus, type 1 (HIV-1), chimeric proteins were constructed by inserting sequences derived from the V3 loop of gp120 into a nontoxic form of Pseudomonas exotoxin (PE). Inserts of 14 or 26 amino acids, constrained by a disulfide bond, were introduced between domains II and III of PE. V3 loop-toxin proteins expressed in Escherichia coli and corresponding to either MN (subtype B) or Thai (subtype E) strains, were recognized by strain-specific monoclonal anti-gp120 antibodies. When loop sequences were introduced into an enzymatically active form of the toxin, there was no loss of toxin-mediated cell killing, suggesting that these sequences were co-transported to the cytosol. Sera from rabbits injected with nontoxic PE-V3 loop chimeras were reactive for strain-specific gp120s in Western blots, immunocapture assays, enzyme-linked immunosorbent assays, and neutralized HIV-1 infectivity. Since toxin vectors were designed to receive oligonucleotide duplexes encoding any V3 loop sequence, this approach should allow for the production of V3 loop-toxin chimeras corresponding to multiple HIV isolates.
引用
收藏
页码:9951 / 9958
页数:8
相关论文
共 50 条
  • [41] IN-VIVO DISTRIBUTION AND CYTOPATHOLOGY OF VARIANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SHOWING RESTRICTED SEQUENCE VARIABILITY IN THE V3 LOOP
    DONALDSON, YK
    BELL, JE
    HOLMES, EC
    HUGHES, ES
    BROWN, HK
    SIMMONDS, P
    JOURNAL OF VIROLOGY, 1994, 68 (09) : 5991 - 6005
  • [42] Protective effects of curcumin against human immunodeficiency virus 1 gp120 V3 loop-induced neuronal injury in rats
    Gong, Zheng
    Yang, Lijuan
    Tang, Hongmei
    Pan, Rui
    Xie, Sai
    Guo, Luyan
    Wang, Junbin
    Deng, Qinyin
    Xiong, Guoyin
    Xing, Yanyan
    Dong, Jun
    NEURAL REGENERATION RESEARCH, 2012, 7 (03) : 171 - 175
  • [43] The tat and C2-V3 envelope genes in the molecular epidemiology of human immunodeficiency virus-1
    Lorenzo, E
    Herrera, RJ
    Lai, SH
    Fischl, MA
    Hill, MD
    VIROLOGY, 1996, 221 (02) : 310 - 317
  • [44] Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop
    Speck, RF
    Wehrly, K
    Platt, EJ
    Atchison, RE
    Charo, IF
    Kabat, D
    Chesebro, B
    Goldsmith, MA
    JOURNAL OF VIROLOGY, 1997, 71 (09) : 7136 - 7139
  • [45] Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen
    Ping, LH
    Cohen, MS
    Hoffman, I
    Vernazza, P
    Seillier-Moiseiwitsch, F
    Chakraborty, H
    Kazembe, P
    Zimba, D
    Maida, M
    Fiscus, SA
    Eron, JJ
    Swanstrom, R
    Nelson, JAE
    JOURNAL OF VIROLOGY, 2000, 74 (19) : 8946 - 8952
  • [46] Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages
    Rabehi, L
    Seddiki, N
    Benjouad, A
    Gluckman, JC
    Gattegno, L
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (18) : 1605 - 1615
  • [47] Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope
    Letvin, NL
    Robinson, S
    Rohne, D
    Axthelm, MK
    Fanton, JW
    Bilska, M
    Palker, TJ
    Liao, HX
    Haynes, BF
    Montefiori, DC
    JOURNAL OF VIROLOGY, 2001, 75 (09) : 4165 - 4175
  • [48] Immune responses following simian/human immunodeficiency virus (SHIV) challenge of rhesus macaques after human immunodeficiency virus (HIV)-1 third variable domain (V3) loop-based genetic immunization
    Le Borgne, S
    Le Grand, R
    Michel, ML
    Vaslin, B
    Boson, B
    Janvier, G
    Aubertin, AM
    Dormont, D
    Rivière, Y
    JOURNAL OF MEDICAL PRIMATOLOGY, 2000, 29 (06) : 371 - 386
  • [49] FLUOROMETRIC CHARACTERIZATION OF HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1) REVERSE-TRANSCRIPTASE
    CASASFINET, JR
    KUMAR, A
    KARPEL, RL
    WILSON, SH
    FASEB JOURNAL, 1992, 6 (01): : A486 - A486
  • [50] Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat
    Lashomb, Abigail L.
    Vigorito, Michael
    Chang, Sulie L.
    JOURNAL OF NEUROVIROLOGY, 2009, 15 (01) : 14 - 24